Moderator
Ue-yu helps researchers and medical doctors utilize state-of-the-art AI technology to innovate their academic research and clinical practices. Serving at the academia-industry-clinic intersection, he has assisted academic laboratories in spinning off their AI technology to industrial corporations and clinical applications, including biotech startups and pharmaceuticals/therapeutics companies.
Before starting his position at UChicago, Ue-yu was invited by the Co-Founder & Chief Scientific Officer of Evozyne Inc, an NVIDIA-funded AI-biotech UChicago-spinoff company, to lead the R&D project collaborating with NVIDIA, Takeda Pharmaceuticals., UChicago, and Northwestern U for developing novel generative AI architectures for protein engineering. The work has demonstrated a significant impact on the drug discovery sector, and was invited to the NVIDIA GTC 2024 and Bio-IT 2024 presentations.
Ue-yu holds a PhD in Physics from University of Toronto. The research outcome of his PhD thesis is being widely utilized by academic/industrial/medical laboratories around the world.
彭威禹博士致力于帮助研究人员与医护人员利用先进的人工智能技术来创新他们的学术研究和临床实践。他在学术界、产业界和临床交叉领域发挥作用，协助学术实验室将他们的人工智能技术转移到工业企业和临床应用中，包括生物技术初创企业和制药/治疗公司。
在加入芝加哥大学之前，彭威禹博士受Evozyne Inc.（一家由NVIDIA资助的人工智能生物技术公司）的联合创始人兼首席科学官之邀，来领导一项NVDIA，武田制药，芝加哥大学，及西北大学合作的蛋白工程AI项目。该工作在药物发现领域产生了重要影响，并受邀参加了NVIDIA GTC 2024和Bio-IT 2024的演示。
彭威禹博士拥有多伦多大学的物理学博士学位。他的博士论文研究成果被世界各地的学术、产业和医疗实验室广泛利用。
Ue-yu Pen
彭威禹
Director of AI/ML and Applied Physics, Department of Pathology and Duchossois Family Institute, UChicago Medicine
人工智能与应用物理总监，芝加哥大学病理系，芝加哥达契亚斯瓦医学研究所，芝加哥大学普利兹克分子工程学院，芝加哥大学进化系统物理研究中心
Panelists
Associate Partner at the McKinsey & Company
麦肯锡副合伙人
联合领导中国区医疗科技及亚洲医疗数字化与分析板块
Adrian Lo
罗万全
Adrian is a leader of McKinsey’s MedTech service line in China, where he advises on growth transformation and global expansion. He has worked with leading multinational and fast- growing innovators on developing growth strategy, innovation, and business model transformation.
He also co-leads the collaboration with QuantumBlack (AI by McKinsey) on digital and analytics in healthcare in Asia, where he has applied cross-functional analytics and tech expertise to transform commercial engagement within life sciences. He has also led multiple digital business building design efforts with leading life sciences organizations on patient- facing engagement and tech-enabled ecosystems.
Adrian has published many articles on China MedTech, including co-author of China MedTech reports at Biocentury China Healthcare Summit (2020-2021), and is a regular speaker at industry forums such as APACMed.
Adrian is from Hong Kong and holds a B.A. from Yale University.
罗先生是麦肯锡在中国医疗科技服务领域的领导者，主要负责增长转型和全球扩张方
向。他曾同多个全球领先的跨国公司和创新企业合作，共同开发增长、创新、与转型
战略。
他还与麦肯锡旗下的AI QuantumBlack共同引领亚洲医疗保健领域的数字化和分析，通 过多元的分析和技术专业知识而改变生命科学领域参与商业的方式。他还领导了多个 数字化业务构建设计项目，并与领先的生命科学组织合作，开展面向患者的参与和技 术支持的生态系统。
罗先生在中国医疗科技领域发表了许多文章，包括担任中国生物世纪健康峰会(2020- 2021)的中国医疗科技报告合著者，并常在诸如APACMed等行业论坛上发言。
本科毕业与耶鲁大学
Founding Partner InScienceWeTrust BioAdvisory, Previous Senior Director of Business Development-S&E, M&A, and alliance management
InScienceWeTrust BioAdvisory创始人
Leon Tang
唐钧
Leon ‘Jun’ Tang, PhD is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community.
Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.
Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.
Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.
唐钧博士是InScienceWeTrust BioAdvisory (一个专注于制药行业东西方跨境合作的公司 )的创始合伙人。唐钧博士同时还是InScienceWeTrust社区的创始人;该社区拥有来自亚 洲生物科技界的2000多名成员。
唐博士目前担任Mianus Capital(一家美国精品医疗私募股权/风险投资基金)的科学顾 问，以及BioSpark(马萨诸塞州的亚洲生物科技专业协会)的顾问，目前专注在眼科领域 。
唐博士曾任上海恒瑞医药生物技术有限公司的商业搜索与评估高级总监，该公司是在香港 证券交易所上市的公共生物技术公司。他还曾在巴克莱投资银行担任生物技术卖方分析师 ，以及在纽约癌症研究所慈善风险投资基金担任高级经理/高级分析师。
唐博士发表了50余篇学术论文，在《Nature Reviews Drg Discovery》、《Lancet Oncology》、《Science Translational Medicine》、《Nature Communications》、《Science Advances》、《PNAS》等期刊上发表。唐博士本科毕业于 天津大学，硕士毕业于南开大学，博士毕业于西奈山伊坎医学院，博士后在纪念斯隆-凯 特琳癌症中心接受培训。
Deloitte Consulting Partner
德勤咨询合伙人
David Xie
谢峥
Dr. David Xie is a partner at Deloitte Consulting with over a decade of experience in the life sciences and healthcare industries. He holds a Ph.D. in Biology and Genomic Science from the University of Chicago, an
MBA focused on Healthcare Innovation from MIT, and a bachelor's degree from Peking University.
Dr. Xie specializes in providing perspectives on hot topics in the life sciences market, advising both multinational and domestic clients on key strategic and operational issues, and developing solutions for
the future of health for businesses. Additionally, he consults for various multinational and domestic clients in the life sciences sector on issues such
as market entry, regulation, pricing/market access, go-to-market strategies,
supply chain, innovation, and organizational change programs.
谢峥博士是德勤咨询公司的合伙人，拥有超过十年的生命科学和医疗保健行业经验。谢博士在芝加哥大学获得生物学和基因组科学的博士学位，持有麻省理工学院的健康创新MBA学位，并在北京大学取得学士学位。
他专注于为多家跨国和国内客户提供关于生命科学市场热点话题的中国视角，就关键的战略和运营问题提供建议，并为企业发展健康未来的解决方案。谢博士还为生命科学领域的多家跨国和国内客户提供关于市场进入、监管、定价/市场准入、市场推广模式、供应链、创新以及组织变革计划等问题的咨询服务。
Healthcare
医疗健康
In the post-pandemic era, patients have moved online at an unprecedented speed, and the gap between China's medical technology and the leading international standards continues to narrow, with new business models gradually emerging. At the same time, centralized procurement further squeezes profit margins, while competition in the vast market becomes increasingly fierce. In this context, how do participants in the medical technology industry view the future development of the industry? What path will Chinese medical technology companies take in their development?
后疫情时代，患者以前所未有的速度向线上迈进，中国医疗科技与国外领先水平的差距不断缩小，新的商业模式逐步显现；同时，带量采购进一步挤压了利润空间，而广阔市场的竞争也愈发激烈。在此背景下，医疗科技行业各参与方是如何看待未来行业发展？中国医疗科技企业将会走出怎样的发展道路？
